Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
60
NCT04073680
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 1, 2020
Completion: Dec 30, 2021